Login to Your Account



BioSpain 2012

Zeltia Group's Success May Energize Spanish Biotechs

By Cormac Sheridan
Staff Writer

Friday, September 21, 2012
europe_resized.jpg

BILBAO, Spain – The coming months will be a crucial period in the development of Zeltia Group, Spain's flagship biotechnology company, which is due to report data from several clinical trials, including a Phase IIb trial of Nypta (tideglusib) in Alzheimer's disease and a Phase III trial of Aplidin (ptilidepsin) in multiple myeloma.

Given Madrid-based Zeltia's overwhelming prominence within the country's otherwise immature sector, success in either indication would represent a major confidence boost for an industry that is facing stiff headwinds.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription